


ASX ANNOUNCEMENT

1 June 2026

Little Green Pharma Ltd (ASX: LGP)

IMPLEMENTATION OF MERGER BETWEEN LITTLE GREEN PHARMA AND CANNATREK



Little Green Pharma Ltd (ASX: LGP) ("**LGP**" or the "**Company**") is pleased to announce that the previously announced scheme of arrangement under which LGP acquires 100% of the issued share capital of Cannatrek Ltd ("**Cannatrek**") ("**Scheme**") has been implemented.

SUCCESSFUL IMPLEMENTATION

The Scheme was approved by Cannatrek shareholders on 10 April 2026 and by the Federal Court of Australia on 25 May 2026.

In accordance with the Scheme:

- all Cannatrek Shares have now been transferred to LGP; and
- eligible Cannatrek shareholders have today been issued the Scheme Consideration for each Cannatrek Share held on the Record Date, being 7:00pm (Melbourne time) on 25 May 2026 ("**Implementation**").

The Scheme Consideration comprises LGP ordinary shares and new LGP contingent value shares, with existing LGP shareholders holding ~39.5% and Cannatrek shareholders holding ~60.5% of the fully diluted issued capital in LGP upon Implementation and prior to the issue of any additional LGP ordinary shares following the conversion of the LGP contingent value shares*

RATIONALE FOR MERGER

The Implementation of the merger brings together two of Australia's most established medicinal cannabis businesses and creates a leading international medicinal cannabis group with vertically integrated operations spanning cultivation, EU-GMP recognised and AU-GMP certified manufacturing, distribution, clinics, digital health platforms, brands and export operations across Australia and Europe.

LGP CANNATREK GROUP CAPABILITY

Cannatrek has built one of Australia’s leading medicinal cannabis businesses, with significant scale in the Australian market, a highly diversified product portfolio, established clinic and distribution capabilities, proprietary digital health assets, and one of Australia’s largest AU-GMP certified medicinal cannabis manufacturing and storage facilities.

As previously outlined, the merger reflects the increasing importance of scale, operational capability, distribution reach and balance sheet strength in both the Australian and international medicinal cannabis markets and is expected to deliver meaningful operational and strategic synergies across manufacturing, cultivation, clinics, distribution, procurement and corporate functions. The merger also brings significant additional capital to fund LGP’s long-held European growth and expansion strategy.

The LGP Cannatrek Group is expected to be well positioned to participate in ongoing global medicinal cannabis industry consolidation and to pursue further international expansion opportunities across Europe and other emerging regulated medicinal cannabis markets.

LEADERSHIP AND BOARD COMPOSITION

Following implementation of the Scheme:

- Mr Brent Dennison has assumed the role of Independent Non-Executive Chair;
- Mr Paul Long continues as Group Chief Executive Officer;
- Mr Michael Lynch Bell continues as an Independent Non-Executive Director;
- Mr Thomas Huppert and Mr Seth Yakatan have joined the Board as Non-Executive Directors;
- Ms Paula Butler has assumed the role of Group Chief Financial Officer;
- Mr Jason Rance assumes the role of Chief Executive Officer (Australia); and
- Mr Alistair Warren continues as Company Secretary and General Counsel.

BOARD RETIREMENTS

The Company also confirms that Dr Neale Fong, Ms Fleeta Solomon and Mr Angus Caithness have retired from the Board following implementation of the merger.

Dr Neale Fong

The Board wishes to sincerely thank Dr Fong for his enormous experience, guidance and counsel over approximately eight years as a director of LGP. Dr Fong has provided invaluable strategic, governance and commercial support to the Company throughout a significant period of growth and evolution. The Board particularly acknowledges Dr Fong’s steady leadership, judgement and support through a number of important strategic and corporate milestones for the Company.

BOARD RETIREMENTS CONTINUED

The Board also wishes to acknowledge and thank Ms Fieta Solomon and Mr Angus Caithness for their extraordinary contributions to LGP over more than nine years.

Ms Fieta Solomon

As founder of LGP, Ms Solomon played a central role in establishing the Company and helping pioneer the medicinal cannabis industry in Australia. Her vision, leadership and long-term commitment were instrumental in building the foundations of the business and positioning LGP as a recognised international medicinal cannabis company with operations spanning Australia and Europe.

Throughout her tenure with the Company, Ms Solomon consistently championed a strongly patient-focused approach and was a passionate advocate for improving patient access to medicinal cannabis treatment, while also supporting expanded clinical research, education and broader understanding of medicinal cannabis therapies. The Board believes Ms Solomon's legacy will include recognition as one of the key founders and pioneers of the Australian medicinal cannabis industry and sincerely thanks her for her extraordinary contribution to both the Company and the broader sector over more than nine years.

Mr Angus Caithness

Mr Caithness has likewise played a pivotal role in the development and growth of the Company over many years and has been a primary engine behind the Company's success, growth and evolution into an international medicinal cannabis business. Mr Caithness was instrumental in the Company's IPO and subsequent growth trajectory and has made substantial contributions across commercial strategy, operations, capital management, financing initiatives, investor engagement and broader corporate development activities. Mr Caithness also played a central role in the acquisition and successful integration of the LGP Denmark facility into the Group, overseeing the continued development of the Company's European operations and sales activities and has been heavily involved in driving the growth and expansion of LGP's international business over many years. His dedication, commercial acumen and commitment to the business have made an enormous contribution to the Company and have helped shape LGP into the organisation it is today.

The present Board also wishes to personally thank each of the retiring directors for their collaboration, professionalism, high standard of ethics and collegiality over many years, including through a number of challenging periods for both the Company and the broader global medicinal cannabis industry.

INCOMING DIRECTORS

The Board also welcomes Mr Brent Dennison, Mr Thomas Huppert and Mr Seth Yakatan to the Board and looks forward to the significant strategic, operational and international experience they bring to the LGP Cannatrek Group.

LGP AND CANNATREK SHAREHOLDERS AND STAFF

The Company also thanks long-term shareholders of both LGP and Cannatrek for their ongoing loyalty and support, welcomes new shareholders to the register, and thanks the employees of both organisations for their professionalism, effort and commitment throughout the merger process.



**Commenting on implementation of the merger,
Independent Non-Executive Chair Brent Dennison said:**

“The successful implementation of this merger creates one of the most substantial and diversified medicinal cannabis businesses in Australia and Europe. We believe the LGP Cannatrek Group has the operational capability, balance sheet strength and strategic positioning to pursue significant growth opportunities and play an active role in the ongoing consolidation of the global medicinal cannabis sector.”

Group CEO Paul Long said:

“This is a highly significant milestone for both businesses. Cannatrek has built an outstanding business with strong brands, manufacturing capability, distribution reach and cash generation, while LGP has developed one of the leading international medicinal cannabis platforms operating across Australia and Europe. We are excited about the opportunities ahead and look forward to executing on the integration process and broader strategic opportunities available to the LGP Cannatrek Group.”



Appendix – Summary of changes to remuneration arrangements for Group CEO Paul Long

The Board has approved certain revised remuneration arrangements for Mr Paul Long in connection with implementation of the merger and his ongoing role as Group CEO of the LGP Cannatrek Group, including:

- increase in fixed annual remuneration to \$500,000 exc super
- award of a change in control bonus equal to 60% of base salary payable in six months’ time
- cancellation of the limited recourse loan associated with the exercise of \$0.30 options in 2019, previously disclosed to the market in the FY2025 Annual Report.

Mr Long has also agreed to cancel all remaining Performance Rights currently held by him.

** Cannatrek shareholders who would otherwise acquire less than a marketable parcel of LGP Shares under the Scheme may have their LGP Share consideration issued to a nominee for sale and will instead receive the net proceeds of sale, while continuing to receive the applicable CV Shares issued under the Scheme.*

This announcement is authorised for release by the Board of LGP

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Group CEO and Director

Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit:
www.computershare.com.au/easyupdate/lgp